Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR2 | P41587 | 6/20 | 0.61 |
| ▸ | VIPR1 | P32241 | 5/20 | 0.61 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.58 |
| ▸ | GLP1R | P43220 | 2/20 | 0.58 |
| ▸ | CCKBR | P32239 | 1/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.57 |
| ▸ | PTH1R | Q03431 | 2/20 | 0.57 |
| ▸ | ECE1 | P42892 | 1/20 | 0.56 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.56 |
| ▸ | TFPI | P10646 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30176471 | 0.95 | VIPR2 (0.63) | VIPR2VIPR1IL23RGLP1RCCKBR | |
| SCHEMBL30261959 | 0.93 | KEAP1 (0.61) | VIPR2VIPR1GLP1RCCKBRKEAP1 | |
| SCHEMBL30262056 | 0.93 | KEAP1 (0.62) | VIPR2VIPR1GLP1RCCKBRKEAP1 | |
| SCHEMBL30390072 | 0.92 | CRHR1 (0.57) | VIPR2VIPR1IL23RGLP1RCCKBR | |
| SCHEMBL29403715 | 0.91 | VIPR1 (0.72) | VIPR2VIPR1GLP1RCCKBRPTH1R | |
| SCHEMBL31182635 | 0.91 | GLP1R (0.64) | VIPR2VIPR1GLP1RCCKBRPTH1R | |
| SCHEMBL30432173 | 0.91 | VIPR1 (0.69) | VIPR2VIPR1GLP1RCCKBRPTH1R | |
| SCHEMBL31174230 | 0.90 | PTH1R (0.63) | VIPR2VIPR1GLP1RCCKBRPTH1R | |
| SCHEMBL29649202 | 0.89 | IL23R (0.60) | VIPR2VIPR1IL23RGLP1RCCKBR | |
| SCHEMBL30176441 | 0.89 | TFPI (0.64) | VIPR2VIPR1GLP1RKEAP1PTH1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737561-A2 | PROCESSES FOR GENERATING ENGINEERED CELLS AND COMPOSITIONS THEREOF | Juno Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4051402-B1 | CELL SELECTION AND/OR STIMULATION DEVICES AND METHODS OF USE | C3S2 GMBH (DE) | 2026-04-29 | — | — | EP | disclosed |
| US-20260078165-A1 | PROCESSES FOR GENERATING ENGINEERED CELLS AND COMPOSITIONS THEREOF | JUNO THERAPEUTICS, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-12522660-B2 | Methods for selection and stimulation of cells and apparatus for same | C3S2 GMBH (DE) | 2026-01-13 | — | — | US | disclosed |
| US-12516099-B2 | Processes for generating engineered cells and compositions thereof | JUNO THERAPEUTICS, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| EP-4647493-A2 | OLIGOMERIC PARTICLE REAGENTS AND METHODS OF USE THEREOF | Juno Therapeutics, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250283037-A1 | METHODS FOR STIMULATING AND TRANSDUCING T CELLS | JUNO THERAPEUTICS GMBH (DE) | 2025-09-11 | — | — | US | disclosed |
| US-20250237628-A1 | CELL SELECTION AND/OR STIMULATION DEVICES AND METHODS OF USE | JUNO THERAPEUTICS GMBH (DE) | 2025-07-24 | — | — | US | disclosed |
| EP-3615653-B1 | OLIGOMERIC PARTICLE REAGENTS AND METHODS OF USE THEREOF | JUNO THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4545964-A2 | CHROMATOGRAPHIC ISOLATION OF CELLS AND OTHER COMPLEX BIOLOGICAL MATERIALS | Juno Therapeutics GmbH (DE) | 2025-04-30 | — | — | EP | disclosed |
| EP-4051402-A1 | CELL SELECTION AND/OR STIMULATION DEVICES AND METHODS OF USE | Juno Therapeutics GmbH (DE) | 2022-09-07 | — | — | EP | disclosed |
| US-11434294-B2 | Binding members to PD-L1 | CELL MEDICA, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| CN-114929360-A | Cell selection and/or stimulation devices and methods of use | 朱诺治疗学有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-20220243223-A1 | METHODS, KITS, AGENTS AND APPARATUSES FOR TRANSDUCTION | JUNO THERAPEUTICS GMBH (DE) | 2022-08-04 | — | — | US | disclosed |
| CN-108474791-B | Method for culturing cells, and kit and apparatus for use in the method | 朱诺治疗学有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20220195388-A1 | METHODS, KITS AND APPARATUS FOR EXPANDING A POPULATION OF CELLS | JUNO THERAPEUTICS GMBH (DE) | 2022-06-23 | — | — | US | disclosed |
| EP-4004545-A1 | METHODS OF ISOLATING A BIOLOGICAL ENTITY | Cell.copedia GmbH (DE) | 2022-06-01 | — | — | EP | disclosed |
| EP-3988920-A1 | METHODS, KITS AND APPARATUS FOR EXPANDING A POPULATION OF CELLS | Juno Therapeutics GmbH (DE) | 2022-04-27 | — | — | EP | disclosed |
| US-11274278-B2 | Methods, kits and apparatus for expanding a population of cells | JUNO THERAPEUTICS GMBH (DE) | 2022-03-15 | — | — | US | disclosed |
| US-11248238-B2 | Methods, kits, agents and apparatuses for transduction | JUNO THERAPEUTICS GMBH (DE) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078165-A1 | PROCESSES FOR GENERATING ENGINEERED CELLS AND COMPOSITIONS THEREOF | CD4, CD69, ICOS | VIPR2 3987/4885VIPR1 3299/4885IL23R 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.